Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Our 22 production lines for finished formulations across four facilities are complimented by three facilities for Active Pharmaceutical Ingredients (API). Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth.
The ability to provide therapeutic medicines on the best quality parameters and at the right price, is the overriding objective for us at Gland Pharma. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. Over the years, we have been able to move ahead on both those counts, to establish a presence across the entire value chain in Injectables.
A manufacturing base with installed capacity of 750 million units per annum spread over seven facilities; proven Research and Development wing; pan-India and global distribution and sales network; affiliation with national and state level healthcare institutions; compliance with all necessary regulatory boards; and a high level of approvals and pending filings in our area of operations, all contribute to our standing in the pharma domain.
Our family of investors and other stakeholders are the driving force that gives us a sharp focus on good governance in all our areas of operations and services. And by doing so, we are reiterating our firm resolve to deliver value and satisfaction.
We are among the largest and fastest growing global pure-play injectable companies with our products being sold in over 60 countries across 5 continents, including the United States, Europe, Canada, Australia, India and other markets. Our key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. We are present in a vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and Related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists.
Our products are mainly used in critical care segment and hence are highly quality driven.
“Gland makes its products to enhance and save the lives of patients worldwide. Drugs that form part of our portfolio are relied upon by doctors and patients in critical care therapies. Gland does not support the use of any of its products for the purpose of capital punishment. In the United States, the drugs manufactured by Gland are imported by and under the legal control of U.S. entities. They are distributed through a highly regulated, complex, vast supply chain for which Gland has no control. Gland is unaware of any distributor marketing or selling its products for lethal injection purposes or of the use of any of its products in such circumstances."